Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$14.86 USD
+0.14 (0.95%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $14.86 0.00 (0.00%) 5:12 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.86 USD
+0.14 (0.95%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $14.86 0.00 (0.00%) 5:12 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data
by Zacks Equity Research
Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
by Zacks Equity Research
The FDA approves SpringWorks' (SWTX) Ogsiveo (nirogacestat) for the treatment of adult patients with desmoid tumors. Shares rise.
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
by Zacks Equity Research
Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
by Zacks Equity Research
The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug
by Zacks Equity Research
Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.
Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates
by Zacks Equity Research
Regulatory setback for Bristol Myers (BMY) and other updates are in focus in the biotech sector.
Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Entrada Therapeutics, Inc. (TRDA) delivered earnings and revenue surprises of 285.45% and 168.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Entrada Therapeutics, Inc. (TRDA) delivered earnings and revenue surprises of -81.40% and 7.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for July 21st
by Zacks Equity Research
TRDA, LPRO, TBBK, BMTX and MOTS have been added to the Zacks Rank #1 (Strong Buy) List on July 21, 2023.
Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More
by Ekta Bagri
Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.
Entrada (TRDA) Down on Regulatory Update for DMD Candidate
by Zacks Equity Research
Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate.
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More
by Zacks Equity Research
Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
by Zacks Equity Research
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.